Immune Checkpoint Inhibitors Market Share Analysis Report, 2023-2032
The global immune checkpoint inhibitors market size was exhibited at USD 37.9 billion in 2022 and it is expected to hit around USD 212.61 billion by 2032 with a registered CAGR of 18.81% during the forecast period 2023 to 2032.
Key Pointers:
Immune Checkpoint Inhibitors Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 45.04 Billion |
|
Market Size by 2032 |
USD 212.61 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 18.81% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Drug Type, Disease Indication, End-Users |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
|
Key companies profiled |
AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), GlaxoSmithKline PLC, Roche Holding AG, Incyte Corporation, Novartis AG, F. Hoffmann-La Roche Ltd. (Genentech Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono Inc.), BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. |
Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body. Immune checkpoints engage when proteins on the surface of immune cells called T cells recognize and bind to partner proteins in other cells, such as some tumor cells. These proteins are called immune checkpoint proteins. When the checkpoint and partner proteins bind together, they send an “off” signal to the T cells. This can prevent the immune system from destroying cancer. Immunotherapy drugs called immune checkpoint inhibitors to work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.
Growth & innovations in the pharmaceutical industry for cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to a better understanding of the disease pathophysiology, the functioning of the tumor cells, and effective ways to tackle the rising cancer rate creates an opportunity for the immune checkpoint inhibitors market. A rise in the number of R&D activities by various key players across the globe and increasing approval of the immune checkpoint inhibitors by the regulatory bodies are expected to drive the global immune checkpoint market over the forecast period and are set to affect the market growth positively.
For instance, in August 2021, GSK plc., a Pharmaceutical and Biotechnology Company, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The growth of the immune checkpoint inhibitors market is expected to be driven by the high potential in untapped, emerging markets, due to the availability of improved healthcare infrastructure, an increase in unmet healthcare needs, a rise in the prevalence of cancer and chronic diseases, and surge in demand for ideal therapeutics for the treatment of cancer.
The healthcare industry in emerging economies is developing at a significant rate, owing to the rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and the increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for the treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs are the factors propelling the market growth. The demand for immune checkpoint inhibitors is not only limited to developed countries but is also being witnessed in developing countries, such as China, Brazil, and India, which fuel the growth of the market. Factors such as the growing geriatric population and rise in the technological advancements in screening & diagnosis of cancer further drive the market growth.
The surge in the use of immune checkpoint inhibitors, owing to the presence of advanced healthcare facilities and a higher number of the target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to developments in healthcare infrastructure with the rise in demand for immune checkpoint inhibitors market.
The Asia-Pacific region exhibits the largest medicine supply and the largest pharmaceutical industry with the availability of raw materials in abundance. This, in turn, drives the growth of the market. Asia-Pacific offers profitable opportunities for key players operating in the immune checkpoint inhibitors market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as the well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides a great opportunity for new entrants in this region.
Immune Checkpoint Inhibitors Market Segmentation
| By Drug Type | By Disease Indication | By End-Users |
|
|
|
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Drug Type
8.1. Immune Checkpoint Inhibitors Market, by Drug Type, 2023-2032
8.1.1 CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Disease Indication
9.1. Immune Checkpoint Inhibitors Market, by Disease Indication, 2023-2032
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Immune Checkpoint Inhibitors Market, By End-Users
10.1. Immune Checkpoint Inhibitors Market, by End-Users, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Specialty Clinics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Academic & Research Institutions
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.1.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.2.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.3.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-Users (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-Users (2020-2032)
Chapter 12. Company Profiles
12.1. AstraZeneca PLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company (ARMO Biosciences.)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Roche Holding AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Incyte Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi, Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA (EMD Serono Inc.)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers